Screener Summaries Updates Institutions Sign In More Updates › Other Events › NSPR Other Events · Jun 11, 2026
InspireMD, Inc. issued a press release on June 11, 2026, announcing 30-day results from the CGUARDIANS II clinical… NSPR InspireMD, Inc.
InspireMD, Inc. issued a press release on June 11, 2026, announcing 30-day results from the CGUARDIANS II clinical trial regarding the CGuard Prime 80 cm implant for use in TCAR procedures. InspireMD, Inc. is a medical device company specializing in neurovascular technologies.
More from InspireMD, Inc. InspireMD amended certain Series J and K warrants to align exercise terms with the anticipated FDA approval of its… Sep 21, 2026 InspireMD reported Q2 2026 revenue of $1.8 million, flat year-over-year, driven by a 21% international growth offset… Aug 17, 2026 InspireMD, Inc. announced on July 23, 2026, that it provided notice to Chief Commercial Officer Shane Gleason that his… Jul 29, 2026 On July 17, 2026, InspireMD, Inc. received notice from Nasdaq that it is not in compliance with Listing Rule… Jul 23, 2026 Raymond W. Cohen resigned from the board of directors, the Audit Committee, and the Compensation Committee of… Jul 2, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
